India, a number one producer of generic medicines(covaxin), is anticipated to play a key position within the race to create a vaccine for COVID-19, with several institutes working on the similar time.
A potential COVID-19 vaccine (first developed in India) has been approved by DCGI (General Administration of Drug Control of India) for Phase 1 and Phase 2 human clinical trials, which are scheduled to be nationwide in July Start.
COVAXIN is jointly developed by Hyderabad-based Bharat Biotech and ICMR (Indian Medical Research Council). It is an inactivated vaccine made from the infectious SARS-CoV-2 virus strain and has shown promise in preclinical studies , Proved the wide application prospects. Safe and effective immune response.
Drug manufacturers around the world are racing to develop vaccines against the new coronavirus; a new virus is a new virus that has never been discovered by humans, which makes the task of creating a vaccine even more difficult.
India is a leading manufacturer of vaccines and generic drugs, and is expected to play a key role in this race, and several institutions are studying different drugs.
In May, the government stated that as many as 30 teams were working on vaccines. A senior scientific adviser to the government said that it usually takes 15 years and the $300 million work is reduced to 12 months.
Similar efforts are being carried out all over the world, and there are many different drugs in different phases of trials. The World Health Organization (WHO) said last week that AstraZeneca’s vaccine may be the main drug candidate.
The British company has begun large-scale mid-term human trials of the drug developed by researchers at Oxford University.
Other vaccines that may be tested include a vaccine from the American company Moderna, which is scheduled to enter phase III clinical trials in mid-July.
The Chinese military has been approved to use candidate vaccines developed in cooperation with CanSino Biologics. According to Reuters, the drug has shown promise in early clinical trials. Ad5-nCoV is one of eight candidate vaccines developed by Chinese companies for human trials.
Earlier last month, the American biopharmaceutical company Gilead Sciences Inc. stated that the five-day course of its antiviral drug Remdesivir showed moderate benefits for patients with moderate COVID-19 symptoms.
According to Reuters, the drug is administered by intravenous injection, and it is the first drug to show improvement in COVID-19 patients in a formal clinical trial.
As pharmaceutical companies scramble to seek this major breakthrough, which could mean millions of profits and millions of lives saved, experts warn that early vaccines may limit the scope of their work.
The pandemic has claimed the lives of 500,000 victims worldwide, including 16,475 in India. The number of confirmed cases exceeds 101 million, among which India’s worst-hit country is India, with close to 550,000.